Acta Haematologica Polonica

Despite recent progress in treatment methods, acute myeloid leukemia (AML) continues to pose significant clinical challenges and is associated with generally unfavorable prognoses. Patients considered fit for intensive therapy are usually treated with cytarabine-anthracycline-based induction chemotherapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for patients with adverse-risk AML and most patients with intermediaterisk AML. The standard therapy for patients who are deemed too poorly for intensive treatment is the combination of azacitidine and venetoclax. AML cells can escape the immune system through various mechanisms, including reduced expression of MHC complex molecules, ligand shedding, manipulation of chemical signaling, and enhanced inhibitory ligand expression. Increased expression of ligands for T-cell-regulation checkpoints is present in AML cells and correlates with worse outcomes. Therefore, this article reviews the current research progress in immune checkpoint inhibitors in AML.

Krzysztof Bieliński

Bartosz Puła

Łukasz Bołkun

Checkpoint inhibitors as potential therapeutics in acute myeloid leukemia

急性髓性白血病中的免疫检查点抑制剂作为潜在治疗药物

Agnieszka Brzozowska

Natalia Bujko-Wasiak

Yuliia Konieva

Wiesław Wiktor Jędrzejczak

Katarzyna Brzeźniakiewicz-Janus

Acute promyelocytic leukemia in patient with chronic myeloid leukemia treated with tyrosine kinase inhibitors

接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者中的急性早幼粒细胞白血病

Marcin Jasiński

Przemysław Krajewski

Małgorzata Paszkowska-Kowalewska

Krzysztof Jamroziak

Sudden central vision loss in a young patient with chronic myeloid leukemia

年轻慢性髓性白血病患者突发中心视力丧失

Joanna Cisek

Anna Dąbrowska

Agnieszka Majk

Krzysztof Czyżewski

Use of vedolizumab in children with steroid-refractory gastro-intestinal graft-versus-host disease

儿童激素难治性胃肠道移植物抗宿主病中使用维多珠单抗

Ahmet Kaya

Mehmet Ali Erkurt

Irfan Kuku

Emin Kaya

Ilhami Berber

Ahmet Sarıcı

Zehra Bozdağ

Soykan Biçim

Süleyman Arslan

Fatma Hilal Yagın

Relationship between reticular fibrosis with platelet surface markers (CD41A, CD42A, CD42B, CD61) and prognostic markers (WBC, PLT) in acute promyelocytic leukemia

急性早幼粒细胞白血病中网状纤维化与血小板表面标志物（CD41A、CD42A、CD42B、CD61）及预后标志物（WBC、PLT）之间的关系

ISSN	0001-5814, 2300-7117
h-index	13

Publication Information	Publisher: Via Medica，Publishing cycle: ，Journal Type: journal，Open Access Journals: Yes
Basic data	Year of publication: 1971，Proportion of original research papers: 0.00%，Self Citation Rate:N.A.， Gold OA Rate: 0.00%
Average review cycle	14 weeks

Acta Haematologica Polonica

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience

Checkpoint inhibitors as potential therapeutics in acute myeloid leukemia

Acute promyelocytic leukemia in patient with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Sudden central vision loss in a young patient with chronic myeloid leukemia

Use of vedolizumab in children with steroid-refractory gastro-intestinal graft-versus-host disease

Relationship between reticular fibrosis with platelet surface markers (CD41A, CD42A, CD42B, CD61) and prognostic markers (WBC, PLT) in acute promyelocytic leukemia

Checkpoint inhibitors as potential therapeutics in acute myeloid leukemia

Acute promyelocytic leukemia in patient with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Sudden central vision loss in a young patient with chronic myeloid leukemia

Use of vedolizumab in children with steroid-refractory gastro-intestinal graft-versus-host disease

Relationship between reticular fibrosis with platelet surface markers (CD41A, CD42A, CD42B, CD61) and prognostic markers (WBC, PLT) in acute promyelocytic leukemia